Compare Adaptive Biotechnologies Corp (ADPT) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Synopsys, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Synopsys, Inc. trades at $430.32 (market cap $83.61B). The key difference: Synopsys, Inc. is far larger — about 25.1× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | SNPS | |
|---|---|---|
Market Cap | $3.33B | $83.61B |
Sector | Health | Technology |
52-Week High | $22.37 | $645.59 |
52-Week Low | $10.24 | $380.47 |
Enterprise Value | $3.19B | $91.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Synopsys (SNPS) trades at $436.63, down 0.12% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.35 exceeding expectations, and maintains robust gross margins of 73.47%. Recent news highlights the company's strategic pivot toward AI-driven design tools, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with a consensus price target of $558.33 implying 28% upside, driven by AI adoption and market positioning. Key risks include high valuation multiples (P/E of 101.21) and execution challenges in shifting business focus. Investors should weigh growth potential against premium pricing and competitive pressures in the semiconductor software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
